Ovid Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate
Ovid Therapeutics Inc. OVID
$2.85
▲ +0.00%
(+$0.00)
📅 Earnings This Week
Open
$2.76
Prev Close
$2.85
Day Range
$2.64 – $2.87
52W Range
$1.18 – $3.11
Market Cap
$556.60M
Beta
0.29
EPS (TTM)
$-0.25
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-05-05 |
| Shares Out. | 195,300,000 |
| Website | ovidrx.com ↗ |
| Phone | 12127764381 |
| Employees | 23 |
| Revenue | $733,000 |
| Gross Profit | $733,000 |
| Net Income | -$15.0M |
| Free Cash Flow | -$54.8M |
| Total Assets | $232.0M |
| Total Liabilities | $22.1M |
| Equity | $209.9M |
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Ovid Therapeutics Inc. is a publicly traded company under the ticker symbol OVID on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-11-01)